Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Novartis : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
07/12/2018 | 06:53pm CEST

By Donato Paolo Mancini

Novartis AG's (NOVN.EB) closed higher on Thursday after jumping on news of a ruling that suggested that market exclusivity for the company's multiple-sclerosis blockbuster drug Gilenya in the U.S. will likely be extended.

"A favorable resolution of the dosage regimen patent litigation" may lengthen the period in which the drug is free from generic competition, according to a Novartis document seen by Dow Jones Newswires.

The note was sent out at around midday Thursday, two analysts told Dow Jones, and shares started climbing around that time. One of the analysts said the market wasn't expecting the decision, so that sent the share price up.

According to the document, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office issued a decision upholding the validity of the dosage-regimen patent on Wednesday. The decision can be appealed, the document said.

Gilenya had sales of $3.19 billion in 2017, according to the company's annual report.

Novartis said it was pleased with the decision, and that it expected to maintain exclusivity until August 2019.

Shares closed up 4.1% at CHF78.94.

Write to Donato Paolo Mancini at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
07/16NOVARTIS : Democrats report on Novartis, Cohen inquiry
07/14NOVARTIS : Michael Cohen contacts were more extensive than previously disclosed
07/13NOVARTIS : Played Down Ties to Trump Lawyer Michael Cohen, Report Says
07/13NOVARTIS : disputes U.S. senators' report on Cohen contract
07/13NOVARTIS AG : half-yearly earnings release
07/13NOVARTIS : to Drop Anti-Infectives Research Programs and Lay Off 140
07/12NOVARTIS : Findings from Novartis Yields New Findings on Pharmaceutical Research..
07/12NOVARTIS : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update
07/12NOVARTIS : Patent Issued for Systems and Methods for Subretinal Delivery of Ther..
07/12NOVARTIS : Patent Issued for Aqueous Pharmaceutical Composition Containing a Bio..
More news
News from SeekingAlpha
07/16DIVIDEND SENSEI'S PORTFOLIO UPDATE 4 : The 3 Essential Things All Investors Need.. 
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/15BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Cytodyn's Acquisition, Novartis Exits Ant.. 
07/15WEEK IN REVIEW : Tasly Biopharma Completes Pre-IPO Round At $1.9 Billion Valuati.. 
07/13ResTORbio - Leading The Charge Against Aging Related Diseases 
Financials ($)
Sales 2018 51 857 M
EBIT 2018 12 814 M
Net income 2018 10 344 M
Debt 2018 13 432 M
Yield 2018 3,71%
P/E ratio 2018 16,66
P/E ratio 2019 19,73
EV / Sales 2018 4,14x
EV / Sales 2019 3,97x
Capitalization 201 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 89,7 $
Spread / Average Target 14%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-3.93%201 464
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193
AMGEN12.66%129 635